Fetal karyotyping after 28 weeks of gestation for late ultrasound findings in a low risk population

Prenatal Diagnosis

Volumn 23, Issue 13, 2003, Pages 1068-1072

  Drummond, C L ^a   Gomes, D Molina ^a   Senat, M V ^a   Audibert, F ^b   Dorion, A ^b   Ville, Y ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Fetal US markers; Invasive procedure; Nuchal translucency; Prenatal diagnosis; Serum markers screening

Indexed keywords

AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CONTROLLED STUDY; FETUS; FETUS BLOOD SAMPLING; FETUS DISEASE; FETUS ECHOGRAPHY; FETUS KARYOTYPING; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; GENE MUTATION; GESTATIONAL AGE; HUMAN; HYDRAMNIOS; INTRAUTERINE GROWTH RETARDATION; KARYOTYPE 46,XX; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TRISOMY 18; TRISOMY 21; TURNER SYNDROME;

ABNORMALITIES, MULTIPLE; ADOLESCENT; ADULT; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; FETAL GROWTH RETARDATION; FRANCE; GESTATIONAL AGE; HUMANS; KARYOTYPING; MEDICAL RECORDS; MIDDLE AGED; NECK; PREGNANCY; PREGNANCY TRIMESTER, THIRD; RETROSPECTIVE STUDIES; TRISOMY; ULTRASONOGRAPHY, PRENATAL;

EID: 0345827664     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.715     Document Type: Article

References (21)

1. Benacerraf BR. 1996. The second-trimester fetus with Down syndrome: detection using sonographic features. Ultrasound Obstet Gynecol 7: 147-155.
2. De Vigan C, Vodovar V, Verite V, Dehe S, Goujard J. 1999. Current French practices for prenatal diagnosis of trisomy 21: a population-based study in Paris, 1992-97. Prenat Diagn 19: 1113-1118.
3. Goodburn SF, Yates JRW, Raggatt PR, et al. 1994. Second-trimester maternal serum screening using alphafetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional program. Prenat Diagn 14: 391-402.
4. Hobbins JC, Lezotte DC, Persutte WH, et al. 2003. An 8-center study to evaluate the utility of mid-term genetic sonograms among high-risk pregnancies. J Ultrasound Med 22: 33-38.
5. Nicolaides KH, Asar G, Bryne D, Mansur C, Marks K. 1992. Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy. Br Med J 304: 867-869.
6. Nicolaides KH, Snijders RJM, Cosden RJM, Berry C, Campbell S. 1992. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 340: 704-707.
7. Noble PL, Abraha HD, Snijders RJM, Sheriwood R, Nicolaides KH. 1995. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free B-hCG and fetal nuchal translucency thickness. Ultrasound Obstet Gynecol 6: 390-395.
8. Nwosu EC, Welch CR, Manasse PR, Walkinshaw SA. 1993. Longitudinal assessment of amniotic fluid index. Br J Obstet Gynaecol 100(9): 816-819.
9. Nyberg DA, Souter VL, El-Bastawissi A, Young S, Luthhardt F, Luthy DA. 2001. Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy. J Ultrasound Med 20: 1053-1063.
10. Pandya P, Snijders R, Johnson S, Brizot M, Nicolaides K. 1995. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynecol 102: 957-962.
11. Persutte WH, Hobbins JC, Nyberg DA, et al. 1998. Trisomy 21 multicenter collaborative project. Am J Obstet Gynecol 178: abstract 47.
12. Rotmensch S, Liberari M, Bronshtein M, et al. 1997. Prenatal sonographic findings in 187 fetuses with Down syndrome. Prenat Diagn 17: 1001-1009.
13. Rozenberg P, Malagrida L, Cuckle H, et al. 2000. Down's syndrome screening with nuchal translucency at 12-14 weeks and maternal serum markers at 14-17 weeks: a prospective study. Hum Reprod 17: 1093-1098.
14. Souter VL, Nyberg DA, El-Bastawissi A, Zebelman A, Luthhardt F, Luthy DA. 2002. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21. Prenat Diagn 22: 175-182.
15. Spencer K, Carpenter P. 1992. Prospective study of prenatal screening for Down syndrome with free beta human chorionic gonadotrophin. Br Med J 307: 764-769.
16. Spencer K, Spencer CE, Power M, Mokaes A, Nicolaides KH. 2000. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynecol 107: 1271-1275.
17. Verdin SM, Whitlow BJ, Lazanakis M, Kadir RA, Chatzipapas I, Economides DL. 2000. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry. Ultrasound Obstet Gynecol 16: 402-406.
18. Vintzileos AM, Egan JFX. 1995. Adjusting the risk for trisomy 21 on the basis of the second-trimester ultrasonography. Am J Obstet Gynecol 172: 837-844.
19. Vintzileos AM, Guzman ER, Smulian JC, Mclean DA, Ananth CV. 1997. Choice of second-trimester genetic sonogram for detection of trisomy 21. Obstet Gynecol 90: 187-190.
20. Wandy NJ, Kennard A. 1997. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 17: 821-829.
21. Yagel S, Anteby EY, Hochner-Celnikier D, Ilana A, Chaap T, Neriah ZB. 1998. The role of midtrimester targeted fetal organ screening combined with triple test and maternal age in the diagnosis of trisomy 21: a retrospective study. Am J Obstet Gynecol 178: 40-45.